Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

aPCC and Emicizumab Safety Study in Congenital Hemophilia A Patients With Inhibitors (SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis)

NCT04563520 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04563520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04563520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
aPCC and Emicizumab Safety Study in Congenital Hemophilia A Patients With Inhibitors (SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis)
Lead sponsor
Emory University
Phase
Phase 3
Overall status
Recruiting
Start date
September 30, 2026
Completion date
March 31, 2027
Enrollment
5 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a